Home
HelpTest ID H2UR HER2 Amplification Associated with Urothelial Carcinoma, FISH, Tissue
Ordering Guidance
This test is only performed on specimens from patients with primary or metastatic urothelial tumors.
This test is not appropriate if the specimen is derived from primary or metastatic breast carcinoma. See H2BR / HER2 Amplification Associated with Breast Cancer, FISH, Tissue. If this test is ordered and the laboratory is informed that the specimen is a primary or metastatic breast carcinoma, it will be canceled and automatically reordered by the laboratory as H2BR.
This test is not appropriate if the specimen is derived from primary or metastatic gastroesophageal carcinoma. See H2GE / HER2 Amplification Associated with Gastroesophageal Cancer, FISH, Tissue. If this test is ordered and the laboratory is informed that the specimen is a primary or metastatic gastroesophageal carcinoma, it will be canceled and automatically reordered by the laboratory as H2GE.
For all other tumor types, order H2MT / HER2 Amplification, Miscellaneous Tumor, FISH, Tissue. If this test is ordered and the laboratory is informed that the specimen is a primary or metastatic colorectal adenocarcinoma, endometrial serous carcinoma, or any other non-breast, non-gastroesophageal, or non-urothelial primary or metastatic tumor, it will be canceled and automatically reordered by the laboratory as H2MT.
This test does not include a pathology consult. If a pathology consultation is requested, order PATHC / Pathology Consultation, and the appropriate testing will be added at the discretion of the pathologist and performed at an additional charge.
Shipping Instructions
Advise Express Mail or equivalent if not on courier service.
Necessary Information
1. A pathology report is required for testing to be performed. If not provided, appropriate testing and/or interpretation may be compromised or delayed. Acceptable pathology reports include working drafts, preliminary pathology, or surgical pathology reports.
2. The following information must be included in the report provided:
-Patient name
-Block number - must be on all blocks, slides, and paperwork
-Date of collection
-Tissue source
-Fixation used AND time in fixation (recommended: >6 hours and <72 hours).
3. A reason for testing must be provided. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Required
Submit only 1 of the following specimens:
Preferred
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tumor tissue block. Blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.
Acceptable
Specimen Type: Tissue slides
Slides: 1 Hematoxylin and eosin stained and 4 unstained
Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 4 consecutive, unstained, positively charged, unbaked slides with 5-micron-thick sections of the tumor tissue. Slides cut from blocks prepared with alternative fixation methods may be acceptable; provide fixation method used.
Forms
If not ordering electronically, complete, print, and send a Oncology Test Request (T729) with the specimen.
Useful For
A predictive marker for patients with both node-positive or node-negative primary and metastatic urothelial cancer
Guiding therapy for patients with primary or metastatic urothelial tumors, as patients with HER2 amplification may be candidates for therapies that target the human epidermal growth factor receptor 2 (HER2) protein (eg, trastuzumab [Herceptin], pertuzumab)
Confirming the presence or absence of HER2 amplification in cases with 2+ (equivocal) HER2 overexpression by immunohistochemistry
Testing Algorithm
This test includes a charge for the probe application, analysis, and professional interpretation of results for 1 probe set (2 individual fluorescence in situ hybridization [FISH] probes). No analysis charges will be incurred if an insufficient number of representative cells are available for analysis.
Note: In accordance with criteria outlined in the 2013 American Society of Clinical Oncology / College of American Pathologists guideline for breast cancer, reflex testing will not be performed using an alternative chromosome 17 probe when the FISH result is equivocal.(1)
Method Name
Fluorescence In Situ Hybridization (FISH)
Reporting Name
HER2, Urothelial Tumor, FISH,TissueSpecimen Type
TissueSpecimen Minimum Volume
Slides: 1 Hematoxylin and eosin-stained and 2 unstained
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Tissue | Ambient (preferred) | |
| Refrigerated | ||
Reference Values
An interpretative report will be provided.
Day(s) Performed
Monday through Friday
Report Available
6 to 8 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88377
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| H2UR | HER2, Urothelial Tumor, FISH,Tissue | 96893-3 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 603107 | Result Summary | 50397-9 |
| 603108 | Interpretation | 69965-2 |
| 603109 | Result | 62356-1 |
| GC034 | Reason for Referral | 42349-1 |
| 603110 | Specimen | 31208-2 |
| 603111 | Source | 85298-8 |
| 603112 | Tissue ID | 80398-1 |
| 603113 | Fixative | 8100-0 |
| 603114 | Method | 85069-3 |
| 603115 | Additional Information | 48767-8 |
| 603116 | Disclaimer | 62364-5 |
| 603117 | Released By | 18771-6 |